


GSK3179106

Chemical Properties

CAS No. : 1627856-64-7
 Formula: C₂₂H₂₁F₄N₃O₄
 Molecular Weight: 467.41
 Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.



Biological Description

Description	GSK3179106 is RET kinase inhibitor with an IC ₅₀ of 0.4 nM
Targets(IC ₅₀)	c-RET
In vitro	The effect of GSK3179106 on human and rat RET enzymatic activity and motesanib on human RET enzymatic activity was determined in an in vitro biochemical homogeneous time-resolved fluorescence (HTRF) assay.
In vivo	GSK3179106 (3 or 10 mg/kg; orally; BID for 3.5 days) reduces the visceromotor response (VMR) compared to rats administered an acetic acid enema and treated with a vehicle.

Solubility Information

Solubility	DMSO: 100 mg/mL (213.94 mM),Sonication is recommended. H ₂ O: < 1 mg/mL (insoluble) (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4 mg/mL (8.56 mM),Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.1394 mL	10.6972 mL	21.3945 mL
5 mM	0.4279 mL	2.1394 mL	4.2789 mL
10 mM	0.2139 mL	1.0697 mL	2.1394 mL
50 mM	0.0428 mL	0.2139 mL	0.4279 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Russell JP, et al. Exploring the Potential of RET Kinase Inhibition for Irritable Bowel Syndrome: A Preclinical Investigation in Rodent Models of Colonic Hypersensitivity. J Pharmacol Exp Ther. 2019 Feb;368(2):299-307.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481